Qt Imaging Holdings

The QTI team has been on an incredible journey, starting with a shared mission to create disruptive innovation to expand access to medical imaging while ensuring superior patient experience and improving health outcomes. We anchor our efforts in medical imaging because when the body can be scanned often and without harm, health conditions can be detected before symptoms appear. Chief among the new advancements in medical imaging is 3D body imaging. Today QTI focuses on our breast imaging technology, which is native 3D, high resolution, and generates reproducible image quality regardless of operator or breast size or tissue type. Current breast imaging paradigm leads to unnecessary concern and cost. Unlike mammography, QTI technology is effective in screening women with dense breasts, or 40% of women in US. 35% of women aged 40-70 do not get screened. Of the 65% of women who get screened, 15% suffer unnecessary callbacks for ultrasounds, MRI, or biopsies. 80% of biopsies are benign. QTI’s technology can be a much-needed alternative for high risk women under 40, as cancers in younger women are usually aggressive and survival outcomes are poor. Our QT Imaging Breast Acoustic CT™ Scanner is the only true 3D imaging device, FDA cleared for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast. There is no ionizing radiation or compression like in mammography or contrast dyes injections like in MRIs. The technology uniquely quantifies breast density. Surface-to-volume ratios and volumetric doubling time growth rate can be calculated to determine significance of lesions and improve specificity. This breast scanning system gives women the choice they deserve to ensure their breast health over time; for healthcare providers, a technology that is accessible, affordable, and accurately visualizes internal structures of the breast; and, for investors, a market segment extension and a purposeful investment opportunity.